Finland· FI-REL-REL41087
Oncept Il-2
A muut immunostimulantit product containing canarypox virus, strain vcp1338, expressing feline interleukin-2 gene, live, registered in Finland by Boehringer Ingelheim Vetmedica GmbH.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, Live
- Manufacturer
- Boehringer Ingelheim Vetmedica GmbH
- Country
- Finland (FI)
- ATC code
- QL03AX
- ATC class
- Muut immunostimulantit
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c3432966-a064-4831-a4de-7c2019893177 GET /v1/drugs/c3432966-a064-4831-a4de-7c2019893177?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine, kylmäkuivattu, ja liuotin, injektionestettä varten, suspensio",
"route": "Ihon alle",
"ddd_unit": null,
"strength": null,
"atc_label": "Muut immunostimulantit",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/2/13/150/001",
"fimea_rel_id": "REL41087",
"authorised_at": "2013-05-03"
}See everything about canarypox virus, strain vcp1338, expressing feline interleukin-2 gene, live.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.